Harbour BioMed announced the appointment of Dr. Adam Zong as President. Dr. Zong will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed. In this role, Dr. Zong will be responsible for strengthening the Company's internal product pipeline, advancing the strategic development of its overall portfolio, and leading asset strategy and partnership initiatives.
He will also play a key role in aligning cross-functional efforts to accelerate development timelines and maximize the value of the Company's pipeline. Dr. Zong brings more than 20 years of global biopharma leadership experience, with a strong track record in portfolio strategy, commercial operations, and business development. His experience spans both multinational pharmaceutical companies and emerging biotechnology organizations.
Prior to joining Harbour BioMed, Dr. Zong served as Principal Consultant at Arc Nouvel Clinical Development Consulting. He also served as the founding Chief Executive Officer of Hengrui Therapeutics U.S., where he led the company's global expansion. Earlier in his career, he held senior leadership roles at Merck & Co., Bristol Myers Squibb, Schering-Plough, and Pfizer, where he managed global franchises, oversaw large-scale commercial portfolios, and led significant business development, licensing, and M&A transactions.
Dr. Zong received his Ph.D. in Oncology and Virology from Rockefeller University and holds an MBA in Finance and Entrepreneurial Management from The Wharton School of the University of Pennsylvania.
